Skip to Main Content

Paper Details

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.
Nat Commun
89
2020
136, ASXL1, CHIP, DNMT3A, IMiD, MM, Multiple myeloma, PPM1D, TET2, TMN, TP53, clonal hematopoiesis of indeterminate, multiple myeloma, patients, plasma, plasma-cell, plasma-cell neoplasm, stem cell product, therapy-related myeloid neoplasm
Author NameAffiliation
Jihye ParkDana-Farber Cancer Institute
Jihye ParkBroad Institute of MIT and Harvard
Jihye ParkDana-Farber Cancer Institute
Jihye ParkBroad Institute of MIT and Harvard
Christopher J GibsonDana-Farber Cancer Institute
Eliezer M Van AllenDana-Farber Cancer Institute
Eliezer M Van AllenDana-Farber Cancer Institute
Jonathan J KeatsTranslational Genomics Research Institute
Chip StewartDana-Farber Cancer Institute
Chip StewartDana-Farber Cancer Institute
Daniel AuclairMultiple Myeloma Research Foundation
Kenneth C AndersonDana-Farber Cancer Institute
Kenneth C AndersonDana-Farber Cancer Institute
David P SteensmaDana-Farber Cancer Institute
Jerome RitzDana-Farber Cancer Institute
Benjamin L EbertDana-Farber Cancer Institute
Benjamin L EbertBroad Institute of MIT and Harvard
Benjamin L EbertHarvard Medical School
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital
Donna NeubergDana-Farber Cancer Institute
  • 1 - 23

Datasets

Release 1.2